The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Kidney Cancer Diagnostics And Therapeutics Market Expected To Scale Between 2026 And 2030?
The kidney cancer diagnostics and therapeutics market has experienced substantial growth in recent years. It is projected to expand from $4.31 billion in 2025 to $4.6 billion in 2026, with a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be ascribed to several factors, including the rising incidence of renal cell carcinoma, improvements in imaging and biopsy techniques, the widespread adoption of targeted therapies, greater awareness of early cancer diagnosis, and the expansion of oncology treatment centers.
The kidney cancer diagnostics and therapeutics market size is projected to experience substantial expansion in the coming years. It is anticipated to grow to $6.08 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. The anticipated growth during the forecast period can be attributed to the rising adoption of immunotherapy regimens, increasing investment in oncology research, the growing use of genomic testing in cancer care, the expansion of precision medicine approaches, and improving access to advanced cancer diagnostics. Major trends in this period include the rising adoption of targeted and immunotherapy treatments, increasing use of advanced imaging for early diagnosis, a growing demand for personalized kidney cancer treatment, the expansion of biomarker-based diagnostic approaches, and an improved integration of diagnostics and therapeutics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp
What Primary Drivers Are Shaping The Kidney Cancer Diagnostics And Therapeutics Market?
The rising occurrence of kidney cancer is projected to stimulate expansion within the kidney cancer diagnostics and therapeutics market. Kidney cancer is a condition that originates when normal cells in one or both kidneys undergo abnormal changes and exhibit uncontrolled growth, resulting in the formation of a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer are crucial for disease management and treatment, offering several benefits for patients, including early detection, accurate diagnosis, treatment selection, personalized medicine, and treatment monitoring. For instance, in May 2024, according to the American Cancer Society, a US-based nonprofit cancer research and advocacy organization, an estimated 81,610 new cases of kidney cancer were expected to be diagnosed in 2024, along with 14,390 projected deaths. Therefore, the expanding prevalence of kidney cancer is anticipated to propel the growth of the kidney cancer diagnostics and therapeutics market.
Which Segment Classifications Are Used In The Kidney Cancer Diagnostics And Therapeutics Market Segment Analysis?
The kidney cancer diagnostics and therapeutics market covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma
2) By Component: Drugs, Diagnostics
3) By Therapy: Targeted Therapy, Immunotherapy
4) By End-Users: Hospitals, Genomics Laboratories
Subsegments:
1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV
2) By Papillary RCC: Type 1, Type 2
3) By Chromophobe RCC: Localized, Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-Muscle Invasive, Muscle Invasive, Metastatic
What Trends Are Affecting The Growth Of The Kidney Cancer Diagnostics And Therapeutics Market?
Leading companies in the kidney cancer diagnostics and therapeutics market are concentrating on advancing renal cell carcinoma (RCC) treatments to enhance patient outcomes and deliver innovative, tailored therapy options for individuals afflicted with this challenging condition. Research into renal cell carcinoma (RCC) is crucial for kidney cancer diagnostics and therapeutics, as it propels the development of novel diagnostic methods and targeted therapies that lead to earlier detection and personalized treatment for patients. For example, in December 2023, Merck, a US-based pharmaceutical company, introduced welireg (belzutifan), which is the first hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) following previous treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This new therapeutic class exhibits significant benefits, including improved progression-free survival and higher response rates when compared to everolimus. The approval of WELIREG marks a critical stride forward in the kidney cancer diagnostics and therapeutics market, offering renewed promise for patients with advancing disease.
Which Firms Are Contributing To The Kidney Cancer Diagnostics And Therapeutics Market Ecosystem?
Major companies operating in the kidney cancer diagnostics and therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co., Ltd., Ipsen S.A., Exelixis Inc., Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Invitae Corporation, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings
Get The Full Kidney Cancer Diagnostics And Therapeutics Market Report:
Which Region Leads The Kidney Cancer Diagnostics And Therapeutics Market In Overall Market Size?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Kidney Cancer Diagnostics And Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Kidney Cancer Diagnostics And Therapeutics Market 2026, By The Business Research Company
Basal Cell Carcinoma Treatment Market Report 2026
Kidney Cancer Drugs Market Report
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report
Renal Biomarkers Market Report
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model